PMC5312497_01
Histopathology (hematoxylin and eosin staining) showing poorly differentiated endometroid endometrial adenocarcinoma with invasion of myometrium less than 50%.
gr1.jpg
PMC5312497_01_gr1.jpg
fig0005
Lymph-vascular space invasion (LVSI) was also positive (Fig. 1).
Computed tomography of pelvis showing enlarged left inguinal lymph node of size 2.4 x 2.6 cm.
gr2.jpg
PMC5312497_01_gr2.jpg
fig0010
Abdomino-pelvic computed tomography (CT) scan revealed enlarged left inguinal lymph node of size 2.4 x 2.6 cm (Fig. 2) and right external iliac lymph node 1 x 1.2 cm.
CT-PET imaging showing (a) hypermetabolic left inguinal lymph node (SUVmax = 15.2) and (b) hypermetabolic left para-aortic lymph node (SUV max = 17.9).
gr3.jpg
PMC5312497_01_gr3.jpg
fig0015
CT- positron emission tomography (PET) imaging showed left inguinal node with standardized uptake volume (SUVmax) 15.2 and the left para-aortic and external iliac nodes with SUV max 17.9 (Fig. 3a and b).
Left inguinal lymph node excisional biopsy showing (a) metastatic endometroid endometrial adenocarcinoma, (b) positive for cytokeratin (CK-7), (c) progesterone receptors (PR) and (d) negative for CK-20.
gr4.jpg
PMC5312497_01_gr4.jpg
fig0020
Specimen was positive for metastatic endometrial carcinoma with immuno-positivity for cytokeratin (CK-7), estrogen receptor (ER) and progesterone receptors (PR) and immuno-negative for CK-20 and CDX2 (Fig. 4a-d).